We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ALVO:OMXICEAlvotech Analysis

Data as of 2026-03-16 - not real-time

$3.61

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Technical outlook is bearish as the short‑term moving average sits below the price while the medium‑term average remains above, creating a negative crossover. Momentum indicators such as the relative strength index are in the lower region, hinting at oversold conditions, yet the MACD line is under its signal, reinforcing bearish sentiment. Trading volume has been on a decline, and the stock is trading near a key support level, suggesting limited buying pressure. Volatility is high and beta is below one, indicating price swings that exceed market movements but with less systematic risk. The market sentiment gauge shows extreme greed, which may be fueling speculative buying despite the weak fundamentals.
Fundamentally, the company shows modest revenue growth and a solid gross margin, but operating cash flow is negative and free cash flow is deeply in the red, reflecting cash‑burn concerns. Debt levels are substantial relative to cash on hand, and the book value per share is negative, resulting in a negative price‑to‑book metric. While the profit margin is positive, operating margin is negative, highlighting earnings pressure. Analyst price targets are far above the current trading level, implying a large potential upside if pipeline milestones are achieved. However, the combination of high debt, negative cash generation, and regulatory hurdles creates considerable execution risk.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • bearish moving‑average crossover
  • negative MACD signal
  • decreasing trading volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • potential pipeline approvals
  • analyst price targets indicating upside
  • ongoing cash‑flow constraints

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • large market opportunity for biosimilars
  • strong gross margin potential
  • future debt reduction through product launches

Key Metrics & Analysis

Financial Health

Revenue Growth10.60%
Profit Margin12.12%
P/E Ratio15.7
ROA1.98%
P/B Ratio-6.1
Op. Cash Flow$-26486000
Free Cash Flow$-84850000
Industry P/E26.4

Technical Analysis

TrendBearish
RSI32.2
Support$3.45
Resistance$4.69
MA 20$4.01
MA 50$4.61
MA 200$7.00
MACDBearish
VolumeDecreasing
Fear & Greed Index79.45

Valuation

Target Price$18.83
Upside/Downside421.70%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.92
Volatility48.69%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.